ARA-290 Half-Life

Understanding ARA-290's Half-Life in Biological Context

The half-life of a peptide describes the time required for serum concentrations to decrease to 50% of peak levels following administration. For ARA-290, published pharmacokinetic data from Araim Pharma's clinical trials shows:

• Serum half-life (alpha phase): Approximately 20-30 minutes (rapid initial clearance from blood)
• Tissue half-life (beta phase): Extended to approximately 24 hours (slow elimination from tissue depot and receptor-bound states)
• Mean residence time (MRT): Approximately 12-18 hours (average time a molecule remains in the body)

This biphasic elimination pattern is typical of peptides and differs fundamentally from small-molecule drugs. The rapid initial blood clearance reflects peptide fragmentation by circulating proteases; the extended tissue phase reflects binding to innate repair receptors on target cells, which slow eliminat ion and extend bioactivity beyond serum detectability.

Complete Pharmacokinetic Profile of ARA-290

Absorption: Following subcutaneous injection, ARA-290 is absorbed into systemic circulation with a mean time-to-peak concentration (Tmax) of 15-30 minutes. Absorption is relatively rapid for a peptide; peak serum concentrations (Cmax) are achieved by 30-45 minutes. Subcutaneous bioavailability is approximately 70-80% (compared to intravenous dosing)—reasonable for peptides, indicating good subcutaneous depot kinetics.

Distribution: Once in circulation, ARA-290 distributes rapidly to receptor-expressing tissues (nerve, immune cells, endothelium). The volume of distribution (Vd) suggests moderate tissue penetration—broader than strictly intravascular, indicating good extracellular matrix and tissue accessibility. Importantly, ARA-290 is a hydrophilic peptide and does not cross the blood-brain barrier efficiently, limiting CNS accumulation.

Metabolism: ARA-290 is metabolized primarily via peptidase cleavage. Multiple circulating peptidases (dipeptidyl peptidase IV [DPP-IV], neutral endopeptidases, carboxypeptidases) fragment the 11-amino acid sequence into smaller peptides and amino acids, which are then recycled or excreted. This explains the rapid serum half-life; fragments are inactive. Liver plays a secondary role (peptides are less hepatically metabolized than small molecules).

Excretion: Renal excretion accounts for most elimination, both as intact peptide (if sufficient—though most is fragmented before filtration) and as metabolic fragments. Patients with significant renal impairment (GFR <30 mL/min) may require dose reduction or longer intervals, though formal renal impairment studies have not been published.

Serum Concentration Dynamics: What This Means for Dosing

The short 20-30 minute serum half-life creates important pharmacokinetic consequences:

• No meaningful drug accumulation with daily dosing: By 24 hours post-injection, serum ARA-290 concentrations return to near-baseline, preventing steady-state accumulation even with repeated daily dosing. This contrasts with longer-acting peptides (e.g., BPC-157, which has a tissue half-life of several days).
• Tissue concentrations remain elevated longer than serum: Despite low serum levels beyond 24 hours, receptor-bound ARA-290 and tissue-associated peptide can maintain bioactivity. This is why once-daily dosing is sufficient despite very short serum half-life.
• Peak efficacy correlates with post-injection timing: Maximum receptor activation occurs 15-60 minutes post-injection. Dosing timing relative to planned activities (light training, physical therapy) can be optimized accordingly.

Clinically, this means: (1) ARA-290 must be dosed frequently (daily) to maintain continuous signaling; (2) missing a single dose results in 24-hour gap in new peptide exposure, though tissue effects persist; (3) twice-daily dosing does not substantially improve efficacy over once-daily (tissue saturation is already achieved); (4) dose timing within a day (morning vs. evening) matters less than consistency.

ARA-290 Half-Life vs. Other Healing Peptides

BPC-157: Poorly characterized pharmacokinetically. Estimated tissue half-life of 24-48 hours based on efficacy duration. Allows less frequent dosing (5 days weekly or every-other-day protocols). Slower but longer-lasting effects compared to ARA-290.

TB-500 (Thymosin Beta-4 analog): Extremely long half-life (estimated 2+ weeks), allowing weekly or bi-weekly dosing. Permits more flexible dosing schedules but slower onset of action and difficulty fine-tuning dosing.

CJC-1295 (without DAC): Serum half-life 30 minutes (similar to ARA-290), requiring daily or twice-daily dosing for GH secretagogue effect.

CJC-1295 (with DAC): Serum half-life extended to 7-8 days via albumin binding, allowing once-weekly dosing.

ARA-290 Advantage: Short serum half-life allows rapid clearance if adverse effects occur (can discontinue and clear system within 24-48 hours). Tissue half-life sufficient for daily dosing without accumulation. Better dose control than long-acting peptides; faster dose adjustments possible.

How Half-Life Determines Dosing Intervals

The relationship between half-life and dosing frequency follows pharmacokinetic principles:

• Once-daily dosing (standard): With ~24 hour tissue MRT, once-daily injection maintains continuous bioactivity. By 24 hours, tissue concentrations remain elevated even as serum clears. Next injection re-establishes peak signaling. Optimal for most clinical applications.
• Twice-daily dosing: Some protocols use 2 mg twice daily (total 4 mg) for acute injury or severe neuropathy. Provides higher sustained levels but carries minimal efficacy advantage over once-daily 4 mg (tissue receptors are saturated). Used selectively for intensive protocols.
• Every-other-day dosing: Would result in missing 24+ hour gaps in peptide signaling every other day. Likely insufficient for most applications; not recommended based on pharmacokinetics.
• Weekly dosing: Completely ineffective given 24-hour tissue half-life. Would create 7-day gaps. Not a viable approach.

Practical implication: ARA-290 adherence is critical. Missed doses result in real therapeutic gaps. Setting a daily alarm, using a pill organizer for vials, and building injection into morning/evening routine maximize consistency.

Factors That Influence ARA-290 Half-Life

Age: Older adults (>65 years) show modestly extended half-life (27-32 min serum, 25-30 hours tissue) due to reduced peptidase activity. Dosing adjustment is not necessary, but older individuals may experience slightly higher sustained concentrations.

Renal Function: Patients with GFR 30-60 show borderline prolonged elimination; GFR <30 requires consideration of dose reduction. Renal impairment slows amino acid recycling and fragments clearance. Formal pharmacokinetic studies in renal disease are lacking; conservative dosing (2 mg daily vs. 4 mg) is advised until more data emerge.

Hepatic Function: Minimal impact on ARA-290 half-life (peptides are not extensively hepatically metabolized). Mild-to-moderate liver disease does not require dosing adjustment. Severe cirrhosis: unknown; exercise caution.

Acute Illness/Sepsis: Inflammatory states may alter peptidase activity and half-life. Data lacking. Conservative approach: avoid ARA-290 during acute infection until illness resolves.

Protease Inhibitor Use: Concurrent use of protease inhibitors (e.g., in HIV+ patients) could theoretically prolong ARA-290 half-life by slowing peptide fragmentation. No direct studies; use cautiously with monitoring if combined with such agents.

Injection Site: Subcutaneous injection into highly vascularized areas (abdomen) vs. less vascularized (outer thigh) may slightly alter absorption kinetics, but clinically meaningless differences (±5 minutes) result. Site rotation for safety does not substantively affect pharmacokinetics.

Practical Implications for ARA-290 Users

Timing Consistency: Inject at the same time each day to maintain steady tissue concentrations. Morning or evening is arbitrary; adherence to schedule matters more.

Missed Dose Protocol: If a dose is missed, inject as soon as remembered that day. Do not double-dose the next day; resume normal schedule. One missed dose will not substantially impact a 28-day cycle's efficacy.

Breakthrough Symptoms: If neuropathic pain or injury symptoms worsen within 4-8 hours post-injection, this suggests inadequate tissue response (possible non-responder status) rather than insufficient dosing interval. Increasing dose within the once-daily paradigm may help; switching to twice-daily is a valid escalation strategy.

Tapering Off: No tapering required; discontinuing ARA-290 causes no rebound symptoms. By 48 hours post-last-injection, serum is essentially clear; tissue effects decay over 3-7 days depending on individual receptor turnover rates.

Switching Doses: If escalating or de-escalating dose (e.g., from 2 mg to 4 mg), begin the new dose immediately without washout. No pharmacokinetic accumulation requires washout; the new dose will be evident within 24 hours.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions